In conclusion, this work demonstrates that there is a limited core molecular response to reduced SMN levels across the different severities of SMA and opens the “field” up for a more targeted approach to SMA treatment with respect to SMA type. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.